 Pulmonary hypertension, pH, is a common complication of many types of interstitial lung disease, ILD. It is characterized by elevated blood pressure in the lungs arteries, which can lead to decreased exercise tolerance, decreased quality of life, and premature death. Diagnosing pH requires a high level of suspicion and non-invasive tests are often used to identify it. Once pH has been confirmed, further testing is necessary to determine the severity of the condition. Treatments for pH include pulmonary vasodilator therapy, inhaled medications, and combinations with antifibrotic drugs. Recent studies have shown promising results from these treatments, but more research is needed to fully understand their potential benefits. Additionally, understanding the role of the vasculature in the pathogenesis of pH could open up new treatment options. This article was authored by Sebastian Dont, Bert Sweenpole, Els van der Kasteel, and others.